Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Ovarian Cancer|Endometrial Cancer|Cervical Cancer
Interventions: DRUG: 852A
Sponsor: Masonic Cancer Center, University of Minnesota
Collaborators: Pfizer